Premium Nahrungsergänzungsmittel | artgerecht

Alectinib – Uses, Mechanism & Side Effects

Alectinib is a targeted cancer medication used to treat ALK-positive non-small cell lung cancer. It selectively inhibits the ALK protein, thereby slowing tumor growth.

Regular tips about health Regular tips about health

Things worth knowing about "Alectinib"

Alectinib is a targeted cancer medication used to treat ALK-positive non-small cell lung cancer. It selectively inhibits the ALK protein, thereby slowing tumor growth.

What is Alectinib?

Alectinib is a targeted cancer therapy belonging to the class of tyrosine kinase inhibitors (TKIs). It is used to treat ALK-positive non-small cell lung cancer (NSCLC) and is marketed under the brand name Alecensa® by Roche. Alectinib is classified as a second-generation ALK inhibitor and has been approved by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and other regulatory authorities worldwide. It is used both as a first-line treatment and in patients who have progressed on prior ALK-inhibitor therapy.

Indication

Alectinib is indicated for:

First-line treatment of adults with ALK-positive advanced NSCLC
Treatment of patients whose disease has progressed following prior therapy with the ALK inhibitor crizotinib

The presence of an ALK gene rearrangement in tumor tissue must be confirmed by a validated diagnostic test before initiating treatment with alectinib.

Mechanism of Action

Alectinib is a highly selective inhibitor of anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase. In ALK-positive NSCLC, chromosomal rearrangements – most commonly the EML4-ALK fusion – result in a constitutively active ALK protein. This overactive kinase drives uncontrolled tumor cell proliferation and inhibits programmed cell death (apoptosis).

By binding to and blocking ALK, alectinib disrupts these oncogenic signaling pathways and halts tumor growth. In addition to ALK, alectinib also inhibits RET (Rearranged during Transfection) kinase. Compared to first-generation ALK inhibitors such as crizotinib, alectinib demonstrates superior activity against several resistance mutations and has excellent central nervous system (CNS) penetration due to its ability to cross the blood-brain barrier effectively.

Dosage and Administration

The recommended dose of alectinib is 600 mg taken orally twice daily (1200 mg per day total), administered with food. The capsules should be swallowed whole and must not be opened or dissolved.

Treatment is continued until disease progression or unacceptable toxicity occurs.
Dose reductions or temporary treatment interruptions may be required in cases of significant side effects.
Dose adjustments for patients with hepatic or renal impairment should be guided by the prescribing physician and the official product labeling.

Side Effects

Like all cancer medications, alectinib may cause side effects. The most common include:

Fatigue and general weakness
Myalgia (muscle pain) and arthralgia (joint pain)
Edema (fluid retention), particularly in the face and limbs
Constipation and gastrointestinal discomfort
Elevated liver enzymes (transaminases) in blood tests
Photosensitivity (increased sensitivity of the skin to sunlight)
Anemia (low red blood cell count)

Less common but potentially serious adverse effects include:

Interstitial lung disease / pneumonitis
Bradycardia (slow heart rate)
Hepatotoxicity (liver damage)
Myopathy (muscle damage) with significantly elevated creatine kinase levels

Regular monitoring (blood counts, liver function tests, heart rate) is recommended throughout treatment.

Clinical Evidence and Efficacy

The clinical efficacy of alectinib has been demonstrated in several pivotal trials:

ALEX Trial (Phase III): In a head-to-head comparison with crizotinib, alectinib showed significantly longer progression-free survival (PFS) and a markedly higher CNS response rate in patients with brain metastases.
ALESIA Trial: Confirmed the findings of the ALEX trial in an Asian patient population.
J-ALEX Trial: A Japanese study that also demonstrated the superiority of alectinib over crizotinib.

Based on this evidence, alectinib is recommended as the preferred first-line therapy for ALK-positive advanced NSCLC in major international oncology guidelines, including those from ESMO and NCCN.

Important Notes for Patients

Alectinib is a prescription-only medication and must only be taken under medical supervision.
Patients should avoid excessive sun exposure and use high-SPF sunscreen during treatment due to the risk of photosensitivity.
Certain medications (e.g., strong CYP3A4 inhibitors or inducers) and grapefruit products may affect alectinib levels in the body. Patients should inform their doctor of all medications and supplements they are taking.
Women of childbearing potential must use effective contraception during treatment and for at least 3 months after the last dose, as alectinib may harm an unborn baby.

References

European Medicines Agency (EMA): Alecensa (Alectinib) – European Public Assessment Report (EPAR). EMA, 2017. Available at: https://www.ema.europa.eu
Peters S, et al. – Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer (ALEX Study). New England Journal of Medicine, 2017; 377(9): 829–838.
ESMO Clinical Practice Guidelines: Metastatic Non-Small-Cell Lung Cancer. European Society for Medical Oncology, 2023. Available at: https://www.esmo.org

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.